These limitations can be overcome by positron emission tomography (PET) using repetitive “whole body PD-L1 imaging” scans to visualize early changes in the uptake of radioactively labeled anti PD-L1 antibodies, not only in one but in all tumor lesions at once, as well as in all non-malignant lymphoid organs and other tissues of interest. This evidence concerns the gene CD274 and neoplasm.